Loading…
← CockpitCompetitor Analysis › 000566.SZ Hainan Haiyao Co., Ltd. Class AOpen in the cockpit ↗

Hainan Haiyao Co., Ltd. Class A000566.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum weak 30
Mkt cap
$642M
US dollars, full cap
Free float
56%
of shares outstanding
$/day
$17.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-10.4 pp
WACC 5.5%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥3.75
1D-0.5%
1W-8.3%
1M-11.1%
3M-34.1%
6M-18.1%
YTD-47.5%
1Y-39.6%
ATR %3.8%
52w lowhigh59.4% off high

What Hainan Haiyao does

Employees: 1,738

Hainan Haiyao at a glance

Size Hainan Haiyao (000566.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $642M, the 3088th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥3.75 on 18 Nov 2026.

Performance Over six months the shares fell 18.1%, against -17.5% for the median peer and -20.0% for the China market (cap-weighted) — 10th lowest of 20 in its peer set.

Growth Revenue fell 18.0% over the last twelve months (peer median +12.2%); the operating margin is -50.0% (peer median 10.0%).

Valuation It trades at 10.6× enterprise value to sales against a peer median of 3.2× (4th most expensive of 17).

Capital Return on invested capital runs 10.4 points below its cost of capital (5.5% WACC).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026Peer median 86000566.SZ 82
Six months, rebased to 100: Hainan Haiyao against the median of its 20 peers (local-currency closes).

Hainan Haiyao financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥673MCN¥825MCN¥971MCN¥1.46BCN¥1.76B
Revenue growth—-15%-33%-17%—
Gross profitCN¥239MCN¥129MCN¥265MCN¥519MCN¥706M
EBITDAn/a-CN¥47.2M-CN¥460MCN¥163MCN¥29.2M
Net income-CN¥533M-CN¥430M-CN¥1.53B-CN¥106MCN¥10.5M
Free cash flow-CN¥115M-CN¥50.9M-CN¥184M-CN¥73.5M-CN¥113M
Capital expenditureCN¥154MCN¥143MCN¥176MCN¥211MCN¥264M
Total debtCN¥3.21BCN¥4.82BCN¥4.56BCN¥4.24BCN¥4.04B

Quarterly statements and history in the cockpit →

Hainan Haiyao competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-40%-20%0%3000164123INNOVACAP300878FDCABUSSPARCBCAX301211OLMA4105ANNXORCHPHARMA688488PHIL002940688658603567000566.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Hainan Haiyao is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%+3,000%0×10×20×3000164123INNOVACAP300878FDCABUSSPARC301211ORCHPHARMA688488PHIL603567000566.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hainan Haiyao is the large dot.

Hainan Haiyao competitors and peer comparison

How Hainan Haiyao compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hainan Haiyao against its 20 peers (data as of 18 Nov 2026)
Measure000566.SZPeer medianRank in peer set
1-month return-11.1%-8.1%8th lowest of 20
6-month return-18.1%-17.5%10th lowest of 20
Distance from 52-week high-59.4%-36.4%5th lowest of 20
Revenue growth (TTM)-18.0%+12.2%2nd lowest of 17
Operating margin-50.0%10.0%lowest of 16
EV / Sales10.6×3.2×4th most expensive of 17
ROIC minus cost of capital-10.4 pp-3.7 pp4th lowest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Hainan Haiyao 000566.SZChina$642M-18%-18%-50%10.6×n/an/a
Beijing Beilu Pharmaceutical 300016.SZChina$641M-19%+23%11%3.0×9.1%+7.9%
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%12.8×36.3%+16.2%
Innova Captab INNOVACAP.NSIndia$645M+20%+37%12%3.4×27.1%+31.4%
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%16.9×n/an/a
FDC FDC.NSIndia$653M+3%+10%14%2.4×25.2%+10.3%
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%1.6×n/an/a
Sun Pharma Advanced Research SPARC.NSIndia$660M+6%+3,141%84%2.5×n/an/a
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%5.3×n/an/a
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%3.0×-8.7%+8.8%
Annexon ANNXUnited States$671M-30%n/an/an/an/an/a
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%6.1×n/an/a
Jiangsu Aidea Pharmaceutical 688488.SSChina$672M-35%+7%8%6.7×31.9%+19.8%
Philogen PHIL.MIItaly$672M-11%+295%79%0.9×n/an/a
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%2.4×10.9%-5.9%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%3.3×10.1%+2.1%
Youcare Pharmaceutical 688658.SSChina$674M-49%-7%-13%1.7×n/an/a
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a25.1×9.1%-25.1%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a

Questions

Which companies are Hainan Haiyao's closest peers?
The cockpit's peer set: Beijing Beilu Pharmaceutical (300016.SZ), Center Laboratories (4123.TWO), Innova Captab (INNOVACAP.NS), Zhejiang Wecome Pharmaceutical (300878.SZ), FDC (FDC.NS), Arbutus Biopharma (ABUS), Sun Pharma Advanced Research (SPARC.NS), Bicara Therapeutics (BCAX).
Is Hainan Haiyao expensive compared with its peers?
On ev / sales it trades at 10.6× against a peer median of 3.2×, 4th most expensive of 17 in its peer set.
How has Hainan Haiyao stock performed?
Over six months to 18 Nov 2026 the shares returned -18.1% against -17.5% for the median peer; over one year -39.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.